Fig 1.
Consolidated standards of reporting trials diagram for patient allocation. The randomization ratio was 2.2.1.
Table 1.
Baseline sociodemographic, smoking-related variables and depression-related variables by trial condition.
Table 2.
Biochemically confirmed abstinence rates, smoking rates and missing data rates by treatment condition (N = 219).
Table 3.
Regression analysis biochemically confirmed by treatment condition using Multiple Imputation.
Table 4.
MLM predicting BDI-II scores at end of treatment, and 3-, 6-, and 12- month follow-ups (n = 210).
Fig 2.
Depressive symptoms by smoking status at the end of treatment, 3-, 6-, and 12-months follow-ups (n = 210).
Note. BDI-II: Beck Depression Inventory–Second edition. Included participants were those who attended at least the first treatment session.
Table 5.
Mean, standard deviations, and effect sizes for depressive symptoms, behavioral activation, and environmental reward from baseline to the end of treatment and at the 3-, 6-, and 12-month follow-ups.
Fig 3.
Mediation model for treatment condition, number of sessions attended and 7-days point prevalence abstinence.
Direct and indirect effects at the end of treatment, and at 3-, 6-, and 12-months follow-ups.